A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

Phase 4 Recruiting 1004 enrolled Zydus Lifesciences Limited

NaSingle-groupOpen-labelTreatment

Summary

A Phase 4, 52 week, single arm, multicentre post marketing surveillance to evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease (CKD)

Timeline

Start: 2023-04-20
Primary completion: 2025-06-30
Completion: 2025-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desidustat	Small molecule	—	Oral

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

Summary

Timeline

Drugs

Indications